| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light.
|
Lancet
|
1985
|
3.27
|
|
2
|
Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.
|
AIDS
|
2000
|
2.38
|
|
3
|
Inactivation of lymphadenopathy associated virus by chemical disinfectants.
|
Lancet
|
1984
|
2.19
|
|
4
|
Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps.
|
J Virol
|
1995
|
2.19
|
|
5
|
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
|
J Antimicrob Chemother
|
2008
|
2.17
|
|
6
|
Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus).
|
Biochem Biophys Res Commun
|
1984
|
1.94
|
|
7
|
Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme.
|
J Virol
|
1996
|
1.84
|
|
8
|
Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle.
|
Virology
|
1993
|
1.74
|
|
9
|
Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.
|
HIV Clin Trials
|
2001
|
1.71
|
|
10
|
Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome.
|
Lancet
|
1985
|
1.70
|
|
11
|
Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.
|
AIDS
|
2001
|
1.63
|
|
12
|
Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor.
|
J Virol
|
1997
|
1.55
|
|
13
|
The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort.
|
J Acquir Immune Defic Syndr
|
2001
|
1.51
|
|
14
|
Management of HIV-related stigma and adherence to HAART: evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA 2003).
|
AIDS Care
|
2006
|
1.41
|
|
15
|
Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells.
|
J Virol
|
1997
|
1.38
|
|
16
|
The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB.
|
J Mol Biol
|
1996
|
1.29
|
|
17
|
Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users.
|
Int J Behav Med
|
2003
|
1.24
|
|
18
|
Vulnerability, unsafe sex and non-adherence to HAART: evidence from a large sample of French HIV/AIDS outpatients.
|
Soc Sci Med
|
2005
|
1.24
|
|
19
|
Factors associated with unprotected anal intercourse among men who have sex with men in Douala, Cameroon.
|
Sex Transm Infect
|
2009
|
1.16
|
|
20
|
Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment.
|
AIDS Care
|
2004
|
1.13
|
|
21
|
Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins.
|
J Gen Virol
|
1998
|
1.12
|
|
22
|
Induction of NF-KB during monocyte differentiation by HIV type 1 infection.
|
J Immunol
|
1991
|
1.10
|
|
23
|
Suicide attempts among people living with HIV in France.
|
AIDS Care
|
2008
|
1.08
|
|
24
|
The replicative impairment of Vif- mutants of human immunodeficiency virus type 1 correlates with an overall defect in viral DNA synthesis.
|
J Gen Virol
|
1998
|
1.02
|
|
25
|
Human transformed trophoblast-derived cells lacking CD4 receptor exhibit restricted permissiveness for human immunodeficiency virus type 1.
|
J Virol
|
1991
|
1.00
|
|
26
|
Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability.
|
AIDS Care
|
2011
|
0.97
|
|
27
|
'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study.
|
AIDS
|
2001
|
0.95
|
|
28
|
Susceptibility of cultured human trophoblasts to infection with human immunodeficiency virus type 1.
|
J Gen Virol
|
1991
|
0.93
|
|
29
|
Differences in replication and cytopathogenicity of human immunodeficiency virus type 1 (HIV-1) are not determined by long terminal repeats (LTR).
|
Virology
|
1990
|
0.93
|
|
30
|
[Non-compliance in HIV-infected patients, supported by a community association].
|
Sante Publique
|
2001
|
0.92
|
|
31
|
Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group.
|
Drug Alcohol Depend
|
2000
|
0.92
|
|
32
|
Enhanced HIV infectivity and changes in GP120 conformation associated with viral incorporation of human leucocyte antigen class I molecules.
|
AIDS
|
1999
|
0.91
|
|
33
|
Oral contraception and unprotected sex with occasional partners of women HIV-infected through injection drug use.
|
AIDS Care
|
2006
|
0.88
|
|
34
|
Time perspective and quality of life among HIV-infected patients in the context of HAART.
|
AIDS Care
|
2007
|
0.88
|
|
35
|
Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs.
|
Int J STD AIDS
|
2001
|
0.88
|
|
36
|
The "Swiss Statement": who knows about it? How do they know? What are its effects on people living with HIV/AIDS?
|
AIDS Care
|
2012
|
0.88
|
|
37
|
Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician.
|
Drug Alcohol Depend
|
2011
|
0.87
|
|
38
|
A role for human immunodeficiency virus type 1 Vpr during infection of peripheral blood mononuclear cells.
|
J Gen Virol
|
1998
|
0.85
|
|
39
|
Stigma, discrimination, and sexual (dis)satisfaction among people living with HIV: results from the "AIDES et toi" survey.
|
AIDS Care
|
2010
|
0.84
|
|
40
|
Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
|
HIV Med
|
2007
|
0.83
|
|
41
|
[A review of socio-behavioural studies on adherence to antiretroviral treatments: beyond biomedical models?].
|
Rev Epidemiol Sante Publique
|
2000
|
0.83
|
|
42
|
[Anhedonia and depressive symptomatology among HIV-infected patients with highly active antiretroviral therapies (ANRS-EN12-VESPA)].
|
Encephale
|
2007
|
0.82
|
|
43
|
Expression of an immunogenic region of HIV by a filamentous bacteriophage vector.
|
Gene
|
1991
|
0.82
|
|
44
|
Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
|
HIV Med
|
2014
|
0.82
|
|
45
|
The HIV-1 Vpr co-activator induces a conformational change in TFIIB.
|
FEBS Lett
|
1999
|
0.80
|
|
46
|
Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau (ESTHER) substudy].
|
HIV Med
|
2015
|
0.80
|
|
47
|
Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008.
|
J Viral Hepat
|
2009
|
0.79
|
|
48
|
Genomic variability of selected LAV-related AIDS retroviruses.
|
AIDS Res
|
1986
|
0.79
|
|
49
|
[Health related quality of life among HIV-HCV co-infected patients].
|
Rev Epidemiol Sante Publique
|
2006
|
0.78
|
|
50
|
Isolation of HIV in a seronegative demented patient without symptoms of immune deficiency.
|
Cancer Detect Prev
|
1988
|
0.78
|
|
51
|
[Health related quality of life and lipodystrophy syndrome among HIV-infected patients].
|
Encephale
|
2006
|
0.78
|
|
52
|
[Infection of insect cell lines by the HIV virus, an agent of AIDS, and a demonstration of insects of African origin infected by this virus].
|
C R Acad Sci III
|
1986
|
0.77
|
|
53
|
Cellular and molecular mechanisms of antiretroviral effects of HPA23.
|
Cancer Detect Prev
|
1988
|
0.77
|
|
54
|
Risk factors for adherence failure in HIV-infected sub-Saharan migrants living in France and travelling back to their native country.
|
Int J STD AIDS
|
2014
|
0.75
|
|
55
|
Long-term nonprogressive human immunodeficiency virus-1 infection in a kidney allograft recipient.
|
Transplantation
|
1998
|
0.75
|
|
56
|
Reduced delays in time to first HIV consultation after diagnosis in France in the antiretroviral therapy era: the possible role of a free care system.
|
HIV Med
|
2011
|
0.75
|
|
57
|
Drug-resistant genotyping in HIV-1 therapy.
|
Lancet
|
1999
|
0.75
|
|
58
|
Cultured trophoblastic choriocarcinoma cells differentially express HIV-1 and cloned provirus.
|
AIDS
|
1991
|
0.75
|
|
59
|
[New tools for preventing and evaluating risk practices for hepatitis C transmission among injection drug users: some reflections on injection rooms and the measurement of risk-taking behaviors].
|
Rev Epidemiol Sante Publique
|
2006
|
0.75
|
|
60
|
[Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
|
Med Mal Infect
|
2007
|
0.75
|
|
61
|
Genetic comparison of LAV-related isolates.
|
Cancer Detect Prev Suppl
|
1987
|
0.75
|
|
62
|
Monoblastic leukemia in an HIV-infected patient: absence of viral expression in RNA blasts.
|
Am J Hematol
|
1996
|
0.75
|
|
63
|
Barebacking and sexual health in the French setting: "NoKondom Zone" workshops.
|
AIDS Care
|
2012
|
0.75
|
|
64
|
[Outcome of HIV-infected patients after 5 years of antiretroviral therapy including a protease inhibitor: the Aproco/Copilote Cohort].
|
Presse Med
|
2005
|
0.75
|